Eli Lilly & Co. (NYSE:LLY)

Major Pharma Sees Fading Short Interest

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Are Loxo Shareholders Getting Enough in the Buyout?

Loxo Oncology Inc. (NASDAQ: LOXO) shares made a massive gain on Monday after it was announced that the firm would be acquired by Eli Lilly and Co. (NYSE: LLY). The ...
Read Full Story »

Short Sellers Hike Bets in Major Pharma Stocks

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Altbaba, AutoDesk, AutoZone, CBS, Eli Lilly, Lululemon, Michael’s, Target and More

The futures traded down big on Thursday morning but were off the lows as investors digest the massive record Wednesday rally on Wall Street. Incredible retail numbers were posted on ...
Read Full Story »

Eli Lilly Scores Solid Results in Psoriatic Arthritis Study

Eli Lilly and Co. (NYSE: LLY) has announced positive results from its late-stage active psoriatic arthritis (PsA) study. This trial is the first completed large head-to-head superiority study in active ...
Read Full Story »

Eli Lilly Receives Crucial FDA Update on Lupus Study

The U.S. Food and Drug Administration (FDA) has granted a Fast Track designation to Eli Lilly and Co.'s (NYSE: LLY) baricitinib, which is being studied for the treatment of systemic lupus ...
Read Full Story »

Major Pharma Stocks See a Surge in Short Interest

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Short Sellers Hike Their Bets in Major Pharma Stocks

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Top Analyst Upgrades and Downgrades: American Eagle, Eli Lilly, GameStop, Intuit, Novavax, Nvidia, Salesforce, Schlumberger and More

Stocks were looking to open higher on Monday after the worst Thanksgiving trading week in seven years. Investors have been forced to see numerous waves of selling in 2018, and ...
Read Full Story »

Short Sellers Pull Back on Major Pharma — With 1 Big Exception

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

New Erectile Dysfunction Treatment Likely to Face Stiff Competition If Approved

The treatment of erectile dysfunction (ED) has helped literally tens of millions of men in America alone. The number of drugs treating ED has grown substantially over the years, and ...
Read Full Story »

Eli Lilly Dips Despite Solid Q3 Results

Eli Lilly and Co. (NYSE: LLY) released its third-quarter financial results before the markets opened on Tuesday. The pharma giant said that it had $1.39 in earnings per share (EPS) ...
Read Full Story »

What to Watch For When Eli Lilly Reports Tuesday Morning

Eli Lilly and Co. (NYSE: LLY) is scheduled to release its most recent quarterly results before the markets open on Tuesday. Consensus estimates from Thomson Reuters are calling for $1.35 ...
Read Full Story »

Top Analyst Upgrades and Downgrades: Aetna, Baker Hughes, Chesapeake Energy, Cognizant, Cummins, Eli Lilly, GE, Qualcomm, Weatherford and More

Stocks were indicated to open much higher on Wednesday after Tuesday's bounce, and earnings may be saving the day, on top of a strong ADP payrolls report. Some investors have ...
Read Full Story »

Dicerna Pharma Teams Up With Eli Lilly for RNAi Technology

Dicerna Pharmaceuticals Inc. (NASDAQ: DRNA) and Eli Lilly and Co. (NYSE: LLY) are partnering up in a global licensing and research collaboration focused on the discovery, development and commercialization of ...
Read Full Story »